

Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: A COSMIC study

Susanne Röhr^{1,*}, Alexander Pabst¹, Steffi G. Riedel-Heller¹, Frank Jessen^{2,3}, Yuda Turana⁴, Yvonne S. Handajani⁵, Carol Brayne⁶, Fiona E. Matthews^{7,8}, Blossom C.M. Stephan⁸, Richard B. Lipton⁹⁻¹¹, Mindy J. Katz⁹, Cuiling Wang¹⁰, Maëlen Guerchet^{12,13}, Pierre-Marie Preux¹²⁻¹⁴, Pascal Mbelesso^{12,13,15}, Karen Ritchie^{16,17}, Marie-Laure Ancelin¹⁶, Isabelle Carrière¹⁶, Antonio Guaita¹⁸, Annalisa Davin¹⁸, Roberta Vaccaro¹⁸, Ki Woong Kim¹⁹⁻²¹, Ji Won Han¹⁹, Seung Wan Suh²⁰, Suzana Shahar²², Normah C. Din²³, Divya Vanoh²⁴, Martin van Boxtel²⁵, Sebastian Köhler²⁵, Mary Ganguli²⁶⁻²⁸, Erin P. Jacobsen²⁶, Beth E. Snitz²⁷, Kaarin J. Anstey^{29,30}, Nicolas Cherbuin³⁰, Shuzo Kumagai³¹, Sanmei Chen³², Kenji Narazaki³³, Tze Pin Ng³⁴, Qi Gao³⁴, Xin Yi Gwee³⁴, Henry Brodaty^{34,35}, Nicole A. Kochan³⁵, Julian Trollor^{35,37}, Antonio Lobo^{38,39}, Raúl López-Antón^{38,40}, Javier Santabárbara^{38,41}, John D. Crawford³⁵, Darren M. Lipnicki³⁵, Perminder S. Sachdev^{35,36}; for Cohort Studies of Memory in an International Consortium (COSMIC)

¹Institute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Leipzig, Germany

²Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany

³German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

⁴Department of Neurology, School of Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia

⁵Center for Health Research, School of Medicine, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia

⁶Department of Public Health and Primary Care, Cambridge University, Cambridge, United Kingdom;

⁷MRC Biostatistics Unit, Institute of Public Health, Cambridge University, Cambridge, United Kingdom

⁸Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom

⁹Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Yeshiva University, New York, New York, USA

¹⁰Saul R. Korey Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Yeshiva University, New York, New York, USA

¹¹Department of Psychiatry and Behavioral Medicine, Albert Einstein College of Medicine, Yeshiva University, New York, New York, USA

¹²INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France

¹³University of Limoges, School of Medicine, Institute of Neuroepidemiology and Tropical Neurology, CNRS FR 3503 GEIST, Limoges, France

¹⁴CHU, Department of Medical Information & Evaluation, Clinical Research and Biostatistic Unit, Limoges, France

¹⁵Department of Neurology, Amitié Hospital, Bangui, Central African Republic

¹⁶INSERM U1061 Neuropsychiatry: Epidemiological and Clinical Research, La Colombière Hospital, Montpellier Cedex 5, Université de Montpellier, Montpellier, France

¹⁷Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom

¹⁸Golgi Cenci Foundation, Corso San Martino 10, 20081 Abbiategrasso, Italy

¹⁹Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

²⁰Department of Psychiatry, Seoul National University, College of Medicine, Seoul, Republic of Korea

²¹Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, Republic of Korea

²²Centre of Healthy Aging and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

²³Centre for Rehabilitation Science and Special Needs, Faculty of Health Science, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

²⁴NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. School of Health Science, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia

- ²⁵Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Maastricht University Medical Center (MUMC), Maastricht, The Netherlands
- ²⁶Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- ²⁷Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- ²⁸Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
- ²⁹Ageing Futures Institute, University of New South Wales, Neuroscience Research Australia, Sydney, NSW, Australia
- ³⁰Centre for Research on Ageing, Health and Wellbeing, College of Health and Medicine, Australian National University, Canberra, ACT, Australia
- ³¹Center for Health Science and Counseling, Kyushu University, 744 Motoooka, Nishi-ku, Fukuoka 819-0395, Japan
- ³²Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
- ³³Faculty of Socio-Environmental Studies, Department of Socio-Environmental Studies, Fukuoka Institute of Technology, 3-30-1 Wajiro-higashi, Higashi-ku, Fukuoka 811-0295, Japan
- ³⁴Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
- ³⁵Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales Sydney, Sydney, Australia
- ³⁶Dementia Collaborative Research Centre, School of Psychiatry, University of New South Wales Sydney, Sydney, Australia
- ³⁷Department of Developmental Disability Neuropsychiatry, University of New South Wales Sydney, Sydney, Australia
- ³⁸Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Ministry of Science and Innovation, Madrid, Spain
- ³⁹Department of Medicine and Psychiatry, Universidad de Zaragoza, Zaragoza, Spain
- ⁴⁰Department of Psychology and Sociology, Universidad de Zaragoza, Zaragoza, Spain
- ⁴¹Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain

***Corresponding author:**

Dr. Susanne Röhr, M.Sc.
Institute of Social Medicine, Occupational Health and Public Health (ISAP),
Medical Faculty, University of Leipzig,
Philipp-Rosenthal-Straße 55
04103 Leipzig, Germany

Phone: +49 341 97 24568

Fax: +49 341 97 24569

E-Mail: susanne.roehr@medizin.uni-leipzig.de

Abstract

Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer's disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence across international cohorts. Therefore, we combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to estimate SCD prevalence. The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3%-24.4%) and IRT (25.6%, 95%CI = 25.1%-26.1%); however, prevalence estimates varied largely between studies (QH: 6.1%, 95%CI = 5.1%-7.0%, to 52.7%, 95%CI = 47.4%-58.0%; IRT: 7.8%, 95%CI = 6.8%-8.9%, to 52.7%, 95%CI = 47.4%-58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian and Black African people compared to White people, in lower- and middle-income countries compared to high-income countries, and in studies conducted in later decades. Data harmonization and application of uniform criteria across diverse cohorts yielded more accurate estimates of SCD prevalence. Having a quarter of older individuals with SCD warrants further investigation of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek medical advice.

Key words

subjective cognitive decline; prevalence; epidemiology; individual participant data; data harmonization; cohort study

Introduction

In light of the projected increase of people living with dementia all around the world, there is a strong interest in early risk stages that may allow early intervention or prevention of dementia. Subjective cognitive decline (SCD) has recently attracted renewed attention on the assumption that it could be the first notable manifestation in the preclinical stage of Alzheimer's disease (AD) and other dementias [1]. SCD refers to a self-experienced decline in cognitive ability in comparison with a previously normal status and without objective cognitive impairment [2]. The updated AD research framework of the National Institute on Aging and Alzheimer's Association (NIA-AA) now recognizes SCD within the cognitively unimpaired stage on the cognitive continuum [3]. Thus, SCD is considered a risk stage for dementia. This is supported by evidence from longitudinal epidemiological data that show an increased risk for mild cognitive impairment (MIC) and dementia in individuals with SCD [1].

Importantly, the subjective perception of declining cognitive capacity can also emerge due to conditions other than AD, for example as part of normal aging, MCI, and in association with depression and anxiety [2]. Primarily, SCD is considered a symptom of preclinical AD only in association with AD biomarkers; however, another view is to consider SCD as a broader behavioral phenotype [4] above and beyond preclinical AD that defines a group of people being concerned about their brain health. This is reflected in an increasing number of individuals who seek medical advice because of SCD [5].

Despite the growing research interest in SCD, the concept still faces methodological challenges regarding its operationalization [6]. Historically, the field has lacked a common terminology and definition since the initial description of a "forgetfulness phase" by Reisberg et al. in 1982 [7]. This resulted in the dissemination of a variety of terms, e.g. subjective memory complaints, subjective memory impairment, forgetfulness, subjective cognitive impairment, or cognitive concerns – to name a few. This hurdle has recently been cleared through the introduction of a consensus definition of SCD in preclinical AD by the working group of the

Subjective Cognitive Decline Initiative (SCD-I) [2]. A standard approach to measure SCD, however, is still lacking [8]. In light of the evolution of the concept, it is unsurprising that previous findings on SCD epidemiology varied, including prevalence estimates. Early studies investigating more general memory complaints reported prevalence between 22% and 56% in community-based samples [9]. Few studies have estimated SCD prevalence building on the SCD-I criteria. In a sample representing the Greek population aged ≥ 65 years without psychiatric conditions, 28% of the cognitively unimpaired participants reported SCD [10]. In a German sample of cognitively unimpaired individuals aged ≥ 75 years, SCD prevalence was 54% [11]. In Chinese residents aged 60 to 80 years, SCD prevalence ranged between 14% and 19% [12]. This, together with a lack of standardized SCD assessment and variations in case definitions, explains variance in reported outcomes. Notably, the occurrence of SCD has almost exclusively been studied in high-income countries (HIC), while evidence from low- and middle-income countries (LMIC) is lacking. The SCD-I emphasized the need for harmonized observational studies that can attenuate some of the limitations associated with SCD operationalization [6].

Study aims

We aimed to estimate SCD prevalence in cognitively unimpaired older individuals by applying uniform SCD criteria to harmonized data from 16 diverse cohort studies of aging. By doing so, we aimed to minimize the influence of both study level and individual level factors, thereby enhancing the generalizability of findings [13]. Moreover, we aimed to examine differences in SCD prevalence according to sociodemographic factors across studies.

Methods

Contributing studies and participants

Cross-sectional population-based individual participant data (IPD) were contributed by 16 member studies of the Cohort Studies of Memory in an International Consortium (COSMIC; <https://cheba.unsw.edu.au/consortia/cosmic/studies>) [14] (Table 1; see Supplemental material Table e-1 for key references). COSMIC brings together international cohort studies of aging to foster cross-cohort analyses on common factors for cognitive decline and dementia. Study-based data were harmonized and pooled. Baseline data were used for all studies except for two that did not assess all variables needed for SCD classification until later waves, i.e. MoVIES provided data for wave 2 (two years after baseline) and PATH for wave 3 (eight years after baseline). The initial sample included individuals aged at least 60 years and without a dementia diagnosis (Table e-2). This was the default option as some studies excluded prevalent dementia cases as per their study design. For the current study, data represented 15 countries from Africa, Asia, Australia, Europe, and North America.

- insert Table 1 -

Ethics

The Human Research Ethics Committee of the University of New South Wales (COSMIC coordinator) approved this study (Ref: HC17292). All contributing studies had previously obtained approval from their respective ethics committees, and it was standard that participants provided written informed consent.

Demographics

Information included age, gender, education, ethnicity, country income, and decade in which a study was conducted. Education was provided as years for most studies. For four cohorts

(ActiveAgeing, EPIDEMCA, ESPRIT, MAAS), education data were provided as categories. For harmonization purposes, categories were assigned discrete year values based on the local education system as informed by the study leaders. A fifth cohort (MoVIES) provided category data for all participants and year values for 73.4%. These data were used to calculate a mean year value for each category that was assigned to individuals missing education year data. For subgroup analysis only, years of education were re-categorized according to the UNESCO International Standard Classification of Education (ISCED) 2011 into pre-/primary education (zero to five years), secondary education (six to nine years), upper-/post-secondary education (ten to 14 years), and tertiary education (>14 years) [15].

Ethnicity was recorded according to self-report. For studies lacking IPD for ethnicity, participants' ethnicity was assigned as the majority ethnicity of the study sample as informed by the study leaders.

Country income was categorized according to the World Bank classification corresponding to the year or mean year in which baseline assessments took place. It is based on the gross national income per capita, i.e. low-, lower middle-, upper middle-, and high-income country.

To account for a potential impact of time trends regarding dementia awareness, we furthermore considered the decade, in which studies were initiated (<1999, 2000-2009, >2009).

Assessment of self-experienced decline in cognitive capacity

Assessment of a self-experienced decline in cognitive capacity varied between studies, though answers to all questions were self-reported during face-to-face interviews. Six studies used a single self-developed question, seven studies used a battery of self-composed questions, and one study used the Subjective Memory Complaints Questionnaire (SMCQ) [16]. Additionally, two studies (ActiveAging and LRGS-TUA) provided a relevant item from the Geriatric Depression Scale (GDS): "Do you feel you have more problems with memory than most?" [17].

In PATH, the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) was administered as self-report, including seven items that addressed whether different facets of memory and recall had changed over time [18]. Data on all identified indicators were then synthesized and harmonized.

One fundamental challenge of integrative data analysis is the evaluation and statistical consideration of between-sample heterogeneity. Since the majority of contributing studies used multiple items to assess a self-experienced decline in cognitive capacity, we followed two complementary strategies to prepare data.

Qualitative harmonization of items for a self-experienced decline in cognitive capacity

The first harmonization strategy followed a qualitative approach [19]. Authors SR and AP independently compared all items assessing self-experienced decline in cognitive capacity between studies and then selected and harmonized them by matching semantically similar items; i.e. if more than one item was available. Inter-rater agreement was high ($K = 0.97$). The original scales for all items were transformed, if necessary, to provide binary responses of presence or absence of a self-experienced decline in cognitive capacity. As a result, we identified and harmonized one common item that bridges the measurement of a self-experienced decline in cognitive capacity across studies (we refer to this item as “item 1”). Table e-3 shows the assessment of the selected items underlying the harmonization of item 1 across studies. Commonly, these items broadly addressed whether the study participant had problems or difficulties with memory; MAAS provided a single item assessing cognitive failures. For six studies, only data on this bridging item 1 was available. For the remaining ten studies, information on additional items was available and considered for harmonization. In addition to the bridging item 1, information from studies with further items available was considered. Overall, we were able to identify and harmonize a total of 32 different items for IRT analysis (Table e-4).

Quantitative harmonization of items for a self-experienced decline in cognitive capacity

The second harmonization strategy followed a quantitative approach in order to develop a measurement model for both common and study-unique items. The goal was to generate scale scores for a generic construct of self-experienced cognitive decline, which is commensurate in meaning and metric across studies and study subpopulations [20]. In particular, we used the 2-Parameter Logistic (2-PL) Item Response Theory (IRT) model as a psychometric approach to evaluate measurement equivalence of items across the 16 studies. IRT allows the localization of both item difficulty and person characteristics on a common latent “trait” that represents self-experienced decline in cognitive capacity, while controlling for between-study heterogeneity of measurement. Higher difficulty values indicate a higher likelihood of a positive response to a certain item [20]. First, we applied an automated bottom-up stepwise item selection procedure to identify a core set of items that builds the basis for IRT analysis [21]. The procedure revealed that 18 of the 32 items (see Table e-4) form a unidimensional factor with acceptable scalability (Loevinger’s $H_{ij} = 0.43$) and good reliability (Cronbach’s Alpha = 0.81). Inspection of parameters of the fitted 2-PL IRT model (i.e., difficulty, discrimination), as well as the evaluation of item characteristics curves led to the exclusion of two additional items with insufficient psychometric properties (item 2, item 5), resulting in a final IRT model with 16 items with partial factorial invariance and acceptable model fit (Root Mean Square Error of Approximation = .02; Comparative Fit Index = .87; Tucker Lewis Index = .85; Standardized Root Mean Square Residuals = .09). Finally, we dichotomized the predicted latent score obtained from the final IRT model at $\theta = 0$ to differentiate individuals with a higher likelihood of present symptoms from those with lower estimated likelihood [22].

Cognitive impairment

The Mini-Mental State Examination (MMSE) was used to assess cognitive impairment [23]. This was the default option as the MMSE was assessed in all but two studies, for which MMSE

scores could be derived from similar tests. For the EAS, Blessed Information Memory Concentration scores were converted to MMSE scores using a validated formula [24, 25]. For the EPIDEMCA cohort, Community Screening Interview for Dementia scores were converted to MMSE scores using a co-calibration table [26, 27].

Functional ability

Functional ability was based on the assessment of instrumental activities of daily living (IADL). Nine studies used the Lawton and Brody IADL Scale [28]. Seven studies each used a different scale, though all had large overlap in key activities (e.g., food preparation, shopping). All instruments are listed in Table S5. For all studies, higher scores indicated higher functionality (after reverse scoring for EPIDEMCA and SydneyMAS).

Depressive and anxiety symptomatology

All studies contributed data for depression and 12 studies for anxiety (anxiety data were not collected in ActiveAging, LEILA75+, LRGS-TUA, and MoVIES). Data were harmonized as per previous COSMIC reports, with all available information considered [29, 30]. Depression was indicated by any of scale scores meeting cut-off, expert diagnosis, self-report, treatment, or use of antidepressant medication (Table e-6). Similarly, anxiety disorders were indicated by any of scale scores meeting cut-off, self-report, or the use of anxiolytics (Table e-7).

Operationalization of SCD cases

SCD cases were uniformly defined and operationalized according to current criteria for SCD and followed recommendations on the implementation of SCD in research, i.e. endorsement of a self-experienced decline in cognitive capacity in the absence of objective cognitive impairment (criterion 1), unimpaired functional ability (criterion 2), exclusion of major depression (criterion 3), and exclusion of anxiety disorder (criterion 4) [1, 6].

Endorsement of a self-experienced decline in cognitive capacity and the presence or absence of major depression or anxiety disorder were determined as above.

Unimpaired cognitive functioning was operationalized as a score higher than 1.5 SDs below the mean of the study-based age-, gender-, and education-adjusted MMSE score. Likewise, unimpaired functional ability was operationalized as a score higher than 1.5 SDs below the mean of the study-based age-, gender-, education-adjusted IADL scores.

Data analysis

Prevalence in our study was defined as the number of SCD cases divided by the total number of cognitively unimpaired individuals, and estimates for both the qualitative harmonization (QH) and quantitative IRT harmonization approach are presented as percentages with 95% confidence intervals (95%CI). All estimates were stratified by study and subsequently by demographic subgroups (age, gender, education, ethnicity, country income, decade). Study-specific prevalence estimates as well as subgroup-specific prevalence estimates and corresponding tests regarding differences in education, ethnicity, country income, and decade were adjusted for age and gender, using the total sample of all 16 studies included in the analysis as the standard population. Gender differences were adjusted for age and vice versa. This allowed for the direct comparison of prevalence estimates between studies and subgroups, including different distributions of core sociodemographic variables [31]. Subgroup comparisons of proportions were tested using Pearson's Chi-square test with Rao/Scott correction. Overall prevalence estimates across studies are reported as unstandardized, since data on standard populations stratified by age and gender were not available.

To illustrate the impact of the individual criteria to quantify SCD cases, we show frequency rates criteria-wise, i.e. cumulatively applying the four criteria for SCD.

Sensitivity analysis for IRT results was performed excluding studies with only the bridging item ('item 1') available. Furthermore, we inspected the contingency of the results of

the two harmonization strategies (QH and IRT). Analyses were performed in Stata 15 MP (Stata Corp, College Station, TX) and R version 3.5.0 [32].

RESULTS

Sample

The initial sample comprised 44,228 dementia-free individuals aged at least 60 years. Inspection of the initial sample led to the exclusion of 1,037 (2.3%) individuals due to study-based missing information on any of the 32 SCD items and 1,049 (2.4%) individuals due to missing information on demographics and/or MMSE. In addition, 2,755 (6.2%) individuals classified as cognitively impaired were excluded, resulting in an analytical sample of 39,387 individuals (Table 2). Mean age of participants in the analytical sample was 73.1 years ($SD = 7.1$; range = 60-105 years). The proportion of women was 57.7%. Education was 9.1 years ($SD = 4.4$) on average.

- insert Table 2 -

Prevalence of SCD in and across studies

Overall, both the QH and IRT approach robustly suggested a SCD prevalence of roughly one in four in the older population without cognitive impairment across studies (QH: 23.8%, 95%CI = 23.3%-24.4%; IRT: 25.6%, 95%CI = 25.1%-26.1%). Study-based age- and gender-standardized SCD prevalence estimates varied largely, ranging from 6.1% (95%CI = 5.1%-7.0%) to 52.7% (95%CI = 47.4%-58.0%) for QH and 7.8% (95%CI = 6.8%-8.9%) to 52.7% (95%CI = 47.4%-58.0%) for IRT. All study-based SCD prevalence estimates according to QH and IRT are shown in the last column in Tables 3 and 4, respectively.

Proportions according to cumulative criteria application

The columns of Tables 3 and 4 show the proportions of the incremental application of the four operationalization criteria for SCD. There was a particular difference in proportions between functional criteria (endorsement of a self-experienced decline in cognitive capacity without objective cognitive impairment and functional ability) and mood criteria (depressive and anxiety symptomatology). When in addition to functional criteria depressive and anxiety symptomatology were addressed, overall proportions decreased from 30.5% (95%CI = 30.0%-30.9%) to 23.8% (95%CI = 23.3%-24.4%) in QH and from 34.5% (95%CI = 34.0%-35.0%) to 25.6% (95%CI = 25.1%-26.1%) in IRT.

- insert Tables 3 & 4 -

Prevalence of SCD according to age group and gender across studies

Reported subgroup results are based on IRT analysis, applying all four SCD criteria. Gender differences were adjusted for age and vice versa. Overall, SCD prevalence was somewhat higher in men compared to women (26.6% vs. 24.9%; $\chi^2(1) = 8.54$; $p = .003$). SCD prevalence significantly differed according to age group ($\chi^2(5) = 51.31$; $p < .001$), which also applied when stratified for gender (men: $\chi^2(5) = 32.42$; $p < .001$; women: $\chi^2(5) = 29.81$; $p < .001$). SCD prevalence was 27.4% (95%CI = 25.8%-28.9%) in ages 60-64 years, then decreased to 23.2% (95% CI = 22.1%-24.2%) in ages 65-69 years, thereafter increased to 24.5% (95%CI = 23.6%-25.5%) in ages 70-74 years, 27.9 (95%CI = 26.5%-29.3%) in ages 75-79 years, and 28.1% (95%CI = 26.2%-30.0%) in ages 80-84 years and 28.1% (95%CI = 25.7%-30.9%) in ages 85+ years. Overall, there was no clear pattern associated with age, except for those aged 65-74 years generally having a lower prevalence than all other age groups. Figure 1 additionally shows SCD prevalence according to age groups stratified by gender.

- insert Figure 1 -

Prevalence of SCD according to education across studies

Age- and gender-standardized SCD prevalence significantly differed according to level of education ($\chi^2(3) = 68.37$; $p < .001$). Individuals with pre-/primary education had higher prevalence of SCD (29.0%; 95%CI = 27.9%-30.2%) compared to individuals with secondary education (25.0%; 95%CI = 24.1%-25.9%), secondary upper/post education (22.7%; 95%CI = 21.8%-23.8%), and tertiary education (26.4%; 95%CI = 24.8%-28.0%).

Prevalence of SCD according to ethnicity across studies

Due to missing information on self-reported ethnicity, this subgroup analysis was based on a subsample of $n = 23,641$ individuals. Age- and gender-standardized SCD prevalence in White people (24.3%; 95%CI = 23.5%-25.1%) was significantly lower than in Asian people (27.2%; 95%CI = 26.3%-28.1%) and Black African people (28.2%; 95%CI = 26.2%-30.3%; $X^2(2) = 29.39$; $p < .001$). Data availability did not allow including further ethnic groups.

Prevalence of SCD according to country income across studies

Age- and gender-standardized SCD prevalence was significantly associated with country income ($\chi^2(2) = 9.56$; $p < .001$). The lower the country income, the higher the SCD prevalence, increasing from 25.1% (95%CI = 24.5%-25.6%) in HIC to 27.4% (95%CI = 24.6%-30.5%) in LMIC to 29.3% (95%CI = 26.4%-32.3%) in LIC.

Prevalence of SCD according to decade of study conduction

Age- and gender-standardized SCD prevalence tended to differ by decade ($\chi^2(2) = 47.77$; $p < .001$), showing an increase over time from 22.4% (95%CI = 21.4%-23.3%) before 1999, then 24.5% (95%CI = 23.1%-25.9%) in the years 2000-2009 to 26.3% (95%CI = 25.9%-27.4%) after 2009.

Sensitivity analysis

Results of the IRT based sensitivity analyses of only studies that used multiple items to assess a subjective experience of cognitive decline are shown in Table e-8, further supporting a pooled SCD prevalence of one in four (26.1%; 95% CI = 25.4%-26.7%).

The contingency of the results returned by the two harmonization approaches was continuously high across prevalence estimates. Using all four operationalization criteria, SCD case classification based on “item 1” by QH and IRT corresponded in 91.4% ($\Phi = 0.77$) and in studies with multiple items in 88.0% ($\Phi = 0.68$) of all cases vs. non-cases.

Discussion

We estimated the prevalence of subjective cognitive decline (SCD) by applying uniform criteria to harmonized individual participant data (IPD). Data represented 16 international population-based cohort studies from 15 countries with over 39,000 individuals at least 60 years old. Across studies, qualitative harmonization (QH) and quantitative harmonization using Item Response Theory (IRT) both robustly suggested a SCD prevalence of roughly one quarter (23.8% and 25.6%) in cognitively unimpaired older individuals. Still, prevalence estimates varied largely between studies (QH: 6.1%-52.7%; IRT: 7.8%-52.7%). However, applying uniform criteria for SCD operationalization to harmonized data helps to reduce the degree of variation in study-based estimates. This is a strength of our study as SCD assessment greatly differed between cohorts and different measurements are known to be associated with outcome variance [33]. Indeed, differences in prevalence estimates are directly associated with test accuracy, and the majority of the items the cohorts used to measure self-experienced decline in cognitive capacity were not psychometrically evaluated. Used in isolation, these potentially imperfect items may give false positive or false negative results, resulting in biased prevalence estimates. However, using multiple items and multiple population groups helps to increase psychometric accuracy, and thus a more accurate estimate of prevalence across studies can be neared [34]. Additionally,

IRT analysis allowed heterogeneity between studies to be addressed statistically, by selecting a set of items that form a unidimensional scale, thus giving confidence that all items measured one construct. Hence, our study suggests that the prevalence of SCD in cognitively unimpaired older individuals is rather banded around 25%, which may give a more accurate idea of SCD prevalence than estimates of single studies do, which are potentially more heavily influenced by measurement issues.

Our results support the notion that SCD is frequent in old age. It is clear that only a proportion of these cases reflect pathological change due to AD or other dementias. The list of non-neurodegenerative conditions that can lead to subjective decline in cognition is long, including, apart from major depression and anxiety, normal aging, various psychiatric, neurologic and medical disorders, substance abuse and medication, as well as personality and cultural factors [2]. The current SCD research definition cannot rule out all other causes, and this is likely reflected in the range of prevalence estimates we found. In this regard, it is interesting to note the difference it made when major depression and anxiety disorders were considered as exclusion criteria in addition to cognitive impairment and functional inability (which some studies have only used), reducing estimates from roughly one third to one quarter. While the exclusion of depression and anxiety disorder is accepted in the criteria, it does highlight the impact criteria can have on prevalence estimates. In addition, many of the above named conditions are associated with an increased risk for cognitive decline and dementia themselves. Vice versa, specific symptoms, especially depressive and anxiety symptoms, can also be a consequence of neuropathological change or co-occur, so that the relationship between SCD, these conditions and neurodegeneration is more complex [2]. In this regard, it seems useful to explore SCD in conjunction with other behavioral symptoms [35]. Like SCD, problems with mood, anxiety, drive, perception, sleep, appetite, agitation, and aggression can be precursors to cognitive decline and dementia, as summarized in the construct mild behavioral

impairment (MBI) [36]. Future investigations could link the two behavioral concepts rather than studying them independently.

Age- and gender-standardized SCD prevalence differed regarding sociodemographic factors. We found slightly higher SCD prevalence in men compared to women. The literature on gender differences in SCD prevalence is inconsistent, some reporting higher prevalence in women [37, 38], others in men [39] or no difference [40]. For both men and women, SCD prevalence differed by age; however, without a clear pattern. This is similar to MCI prevalence, but different to dementia prevalence that shows an increase with aging [41].

SCD prevalence was highest in individuals with less education, as previously reported by others [42]. While the prevalence decreased with increasing levels of education, there was a tendency to increase again among those with the highest education levels. In general, higher educational attainment is thought to provide resilience against neuropathology [43]. This could be expected to lead to a delay in symptom onset and therefore, potentially, a lower SCD prevalence associated with higher levels of education. However, our finding of higher SCD prevalence in those with the highest education suggests otherwise, and possibly points to increased awareness of or alertness to subtle cognitive changes in this group.

Regarding ethnicity, we found higher SCD prevalence in individuals of Asian and African ancestry compared to individuals of European ancestry. SCD and ethnicity is largely unexplored. One study within the US reported similar levels of SCD for African Americans and Whites [44], whereas in another SCD was lower in Asians compared to Whites and highest in Black Americans and American Indians [42]. Our results should be interpreted with caution as data on ethnicity were limited and may not be representative. Additionally, SCD prevalence was lower in HIC compared to LMIC. From an ecobiopsychosocial perspective, this supports the notion that environments with higher socioeconomic resources (e.g., better health care, better educational opportunities, better lifestyle infrastructure) may be beneficial for population health [45]. Indeed, dementia incidence has been observed to have slightly declined in recent

decades in Western high-income countries, supporting such an assumption [46]. Opposed to that, we found a trend of increasing SCD prevalence over decades from before 1999 to after 2009. On the one hand, this could be attributed to increasing public health awareness regarding dementia, or, on the other hand, to the fact, that latter data included more studies from LMIC whereas early studies were exclusively from HIC. However, as much of the increase in numbers of people living with dementia takes place in LMIC [47], there may be indeed a trend towards increasing SCD.

Regardless of causes or consequences, SCD is a serious issue for individuals who experience it. SCD has been associated with concerns [48], lower health-related quality of life [49], increased help-seeking behavior and health care utilization [50]. Thus, SCD has a negative impact on the individual, but also on society through creating additional costs [50]. Having roughly one quarter of the cognitively unimpaired older population experiencing SCD poses the question ‘what to do about it?’. A systematic review and meta-analysis of interventions for SCD targeting well-being, meta-cognition and/or objective cognitive performance reported a lack of high-quality research, but nevertheless found that psychological interventions may be beneficial for well-being and meta-cognition in SCD, though not for cognitive performance [51]. Furthermore, the same study reported a lack of evidence regarding lifestyle and pharmacological interventions. The SCD-I recently argued in support of tailored diagnostic processes that identify underlying medical conditions in individuals with SCD who present to physicians [5]. If no cause can be identified, they suggest to inform about SCD and dementia risk. From there, a watch and wait strategy could be adopted. A comprehensive approach to deal with SCD, if no treatable underlying condition can be identified, is perhaps education about modifiable health and lifestyle factors for brain health. Increasing evidence highlights that, among other factors, improved management of diabetes, hypertension and obesity as well as proactive lifestyle behaviors regarding physical, cognitive and social activity, can promote

brain health and may mitigate dementia risk [52]. It could be beneficial to adopt such strategies as early as in SCD.

Limitations

We were able to consider a set of the most agreed upon criteria to define and operationalize SCD; however, there may be factors not considered in these criteria that influence prevalence estimates of SCD. From this perspective, our reported SCD prevalence may be an overestimate.

Regarding IRT-based estimation of prevalence, we were not able to specify a cutoff other than $\theta = 0$ to differentiate between SCD cases and non-cases, as a gold standard is not available. Moreover, fit indices of our IRT models were acceptable, but indicated room for improvement, which should be considered when possibly developing a standardized measurement of SCD. Though we were able to methodologically tackle heterogeneity in SCD measurement across studies, estimates for individual studies are likely influenced by the type of questions asked. This could be one of the reasons for the large differences in prevalence between the studies, and calls for a standardized and psychometrically sound instrument for SCD. Also, many items to assess a self-experience in cognitive capacity did not cover perceptions of change over time, the majority instead asked about current problems with memory – an acknowledged limitation in SCD research. Future studies may also explore how study-based characteristics beyond age and gender contribute to SCD prevalence variation between studies. Ultimately, only standardized and valid SCD measurement will overcome these limitations, and the SCD field should focus on the development of such an instrument. Our IRT-based item analysis can provide useful information for this. For now, the comparable results from two complimentary approaches to estimate SCD prevalence across a set of diverse studies, further supported by similar results from sensitivity analyses, provide a more accurate picture of SCD occurrence.

Conclusions

One in four cognitively unimpaired individuals above 60 years of age is estimated to experience and report SCD. However, SCD is likely to indicate preclinical AD or other dementing disorders in only the minority of cases. Nevertheless, the frequent occurrence of SCD warrants further research of its significance in preclinical AD and non-AD dementias, and, importantly, on ways to manage SCD in clinical practice. The development and application of a standardized measure to assess SCD is imperative to further our understanding of SCD.

Declarations

Funding

Susanne Röhr was supported by the LIFE—Leipzig Research Center for Civilization Diseases, University of Leipzig, funded by the European Social Fund and the Free State of Saxony (grant number LIFE-103 P1). This work was further supported by a grant from the Hans and Ilse Breuer Foundation. Funding for COSMIC comes from a National Health and Medical Research Council of Australia Program Grant (ID 1093083) (PSS, HB), the National Institute On Aging of the National Institutes of Health under Award Number RF1AG057531 (PSS, MG, RBL, KR, KWK, HB), and philanthropic contributions to The Dementia Momentum Fund (UNSW Project ID PS38235). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. Funding for each of the contributing studies is as follows: ActiveAging: no funding; CFAS: major awards from the Medical Research Council and the Department of Health, UK; EAS: Supported in part by National Institutes of Health grants NIA 2 P01 AG03949, the Leonard and Sylvia Marx Foundation, and the Czap Foundation; EPIDEMCA: French National Research Agency (ANR-09-MNPS-009-01); ESPRIT: Novartis; Invece.Ab: Financed with own

funds and supported in part by "Federazione Alzheimer Italia", Milan, Italy (AG); KLOSCAD: the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [Grant No. HI09C1379 (A092077)]; LEILA75+: the Interdisciplinary Centre for Clinical Research at the University of Leipzig (Interdisziplinäres Zentrum für Klinische Forschung/IZKF; grant 01KS9504); LRGS-TUA: Ministry of Education Longterm Research Grant Scheme (LRGS/BU/2012/UKM–UKM/K/01); MAAS: The Netherlands Organization for Scientific Research (NOW). Grant Number: 002.005.019; MoVIES: Grant # R01AG07562 from the National Institute on Aging, National Institutes of Health, United States Department of Health and Human Services; PATH: National Health and Medical Research Council of Australia grants 973302, 179805, 157125 and 1002160; SGS: JSPS KAKENHI Grant Number JP17K09146; SLASII: The SLAS2 study was supported by research grants from the Agency for Science Technology and Research (A*STAR) Biomedical Research Council (BMRC) <https://www.a-star.edu.sg/> [Grants 03/1/21/17/214 and 08/1/21/19/567] and the National Medical Research Council <http://www.nmrc.gov.sg/> [Grant: NMRC/1108/2007]; ZARADEMP: Supported by grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, Madrid, Spain (grants 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, G03/128), and the Fondo Europeo de Desarrollo Regional (FEDER) of the European Union and Gobierno de Aragón, Group #19.

Conflict of interests

None.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. The Human Research Ethics Committee of the University of New South Wales (COSMIC coordinator) approved this study (Ref: HC17292). All contributing studies had previously obtained approval

from their respective ethics committees (see below). Informed consent was obtained from all individual participants by the contributing studies.

Study	Institutional Review Board
ActiveAging	School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia Ethics Committee (approval 03/04/3014&01/05/2015)
CFAS	Anglia and Oxford Multi-centre Research Ethics Committee (MREC) - 99/5/22; Eastern MREC – 99/5/22; Eastern MREC – 05/MRE05/37; NRES Committee East of England – 05/MRE05/37
EAS	Albert Einstein College of Medicine Institutional Review Board (Approval#1996-175)
EPIDEMCA	Ethical committees, supervised by Ministry of Public Health in CAR (8/UB/FACSS/CSCVPER/11) and the Comité d’Ethique de la Recherche en Sciences de Santé in ROC (00000204/DGRST/CERSSA), approved the study protocol, as well as the “Comité de la Protection des Personnes Sud-Ouest Outre-Mer” in France (SOOM4/CE/3).
ESPRIT	Ethics committee (CCPPRB) of the Kremlin Bicetre hospital (n° registered 99-28)
Invece.Ab	Ethics Committee of the University of Pavia (#3/2009)
KLOSCAD	Institutional Review Board of Seoul National University Bundang Hospital, Korea (IRB No. B-0912/089-010)
LEILA75+	Ethics committee of the University of Leipzig (C7 79934700)
LRGS-TUA	Medical Research and Ethics Committee of Universiti Kebangsaan Malaysia (NN-060-2013). Ministry of Education Longterm Research Grant Scheme (LRGS/BU/2012/UKM–UKM/K/01).
MAAS	Ethics committee of Maastricht University Medical Centre (MEC05-107)
MoVIES	University of Pittsburgh Institutional Review Board (IRB# 961263-0110)
PATH	Australian National University Human Research Ethics Committee (#M9807, #2002/189, #2006/314, # 2010/542, #2001/2, #2009/039)
SGS	Institutional Review Board of the Institute of Health Science, Kyushu University (IHS-2010-22)
SLASII	National University of Singapore Institutional Review Board (NUS IRB 04-140, 17 June 2004)
Sydney MAS	University of New South Wales Human Research Ethics Committee (approval #14327)
ZARADEMP	Ethics committee of the Zaragoza University Hospital (CEICA # CP16/2012)

References

1. Slot RER, Sikkes SAM, Berkhof J, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. *Alzheimers Dement.* 2019;15:465–76.
2. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement.* 2014;10:844–52.
3. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14:535–62.
4. Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. *Annu Rev Clin Psychol.* 2017;13:369–96.
5. Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. *Lancet Neurology.* 2020;19:195–278.
6. Molinuevo JL, Rabin LA, Amariglio R, et al. Implementation of subjective cognitive decline criteria in research studies. *Alzheimers Dement.* 2017;13:296–311.
7. Reisberg B, Ferris SH, Leon MJ de, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. *Am J Psychiatry.* 1982;139:1136–39.
8. Rabin LA, Smart CM, Crane PK, et al. Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. *J Alzheimers Dis.* 2015;48Suppl1:S63–86.
9. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. *Int J Geriatr Psychiatry.* 2000;15:983–91.
10. Vlachos GS, Cosentino S, Kosmidis MH, et al. Prevalence and determinants of subjective cognitive decline in a representative Greek elderly population. *Int J Geriatr Psychiatry.* 2019;34(6):846–854.

11. Roehr S, Riedel-Heller SG, Kaduszkiewicz H, et al. Is function in instrumental activities of daily living a useful feature in predicting Alzheimer's disease dementia in subjective cognitive decline? *Int J Geriatr Psychiatry*. 2019;34:193–203.
12. Hao L, Wang X, Zhang L, et al. Prevalence, risk factors, and complaints screening tool exploration of subjective cognitive decline in a large cohort of the Chinese population. *J Alzheimers Dis*. 2017;60:371–88.
13. Thompson A. Thinking big: large-scale collaborative research in observational epidemiology. *Eur J Epidemiol*. 2009;24:727–31.
14. Sachdev PS, Lipnicki DM, Kochan NA, et al. COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. *BMC Neurol*. 2013;13:165.
15. Schneider SL. The International Standard Classification of Education 2011. In: *Class and Stratification Analysis*: 365–79.
16. Youn JC, Kim KW, Lee DY, et al. Development of the Subjective Memory Complaints Questionnaire. *Dement Geriatr Cogn Disord*. 2009;27(4):310–17.
17. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. *Clin Gerontol*. 1986;5:165–73.
18. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (ICODE): socio-demographic correlates, reliability, validity and some norms. *Psychol Med*. 1989;19:1015–22.
19. Gatz M, Reynolds CA, Finkel D, Hahn CJ, Zhou Y, Zavala C. Data Harmonization in Aging Research: Not so Fast. *Exp Aging Res*. 2015;41:475–95.
20. Bauer DJ, Hussong AM. Psychometric approaches for developing commensurate measures across independent studies: traditional and new models. *Psychol Methods*. 2009;14:101–25.

21. Straat JH, van der Ark LA, Sijtsma K. Comparing Optimization Algorithms for Item Selection in Mokken Scale Analysis. *J Classif.* 2013;30:75–99.
22. Raykov T, Marcoulides GA. *A course in item response theory and modeling with Stata.* College Station, Texas: Stata Press; 2018. A Stata Press publication.
23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975;12:189–198.
24. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. *Br J Psychiatry.* 1968;114:797–811.
25. Thal LJ, Grundman M, Golden R. Alzheimer’s disease: a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam. *Neurology.* 1986;36:262–64.
26. Hall KS, Gao S, Emsley CL, Ogunniyi AO, Morgan O, Hendrie HC. Community screening interview for dementia (CSI ‘D’); performance in five disparate study sites. *Int J Geriatr Psychiatry.* 2000;15:521–31.
27. Crane PK, Narasimhalu K, Gibbons LE, et al. Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. *J Clin Epidemiol.* 2008;61:1018–27.
28. Lawton MP, Brody EM. Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living¹. *The Gerontologist.* 1969;9:179–86.
29. Lipnicki DM, Crawford JD, Dutta R, et al. Age-related cognitive decline and associations with sex, education and apolipoprotein E genotype across ethnocultural groups and geographic regions: a collaborative cohort study. *PLOS Medicine.* 2017;14:e1002261.

30. Lipnicki DM, Makkar SR, Crawford JD, et al. Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study. *PLoS Medicine*. 2019;16:e1002853.
31. van Belle G, Fisher L. *Biostatistics: A methodology for the health sciences*. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2004. Wiley series in probability and statistics.
32. Team RC. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing, 2007.
33. Grabe M. *Measurement Uncertainties in Science and Technology*. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg, 2005.
34. Hui SL, Walter SD. Estimating the error rates of diagnostic tests. *Biometrics*. 1980;36:167–71.
35. Donovan NJ, Amariglio RE, Zoller AS, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. *Am J Geriatr Psychiatry*. 2014;22:1642–51.
36. Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. *Alzheimers Dement*. 2016;12:195–202.
37. Kim J-M, Stewart R, Shin I-S, Choi S-K, Yoon J-S. Subjective memory impairment, cognitive function and depression—a community study in older Koreans. *Dement Geriatr Cogn Disord*. 2003;15:218–225.
38. Müller-Gerards D, Weimar C, Abramowski J, et al. Subjective cognitive decline, APOE ϵ 4, and incident mild cognitive impairment in men and women. *Alzheimers Dement: DADM*. 2019;11:221–230.
39. Wang L, van Belle G, Crane PK, et al. Subjective Memory Deterioration and Future Dementia in People Aged 65 and Older. *J Am Geriatr Soc*. 2004;52:2045–51.

40. Buckley R, Saling MM, Ames D, et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. *Int Psychogeriatr*. 2013;25:1307–1315.
41. Sachdev PS, Lipnicki DM, Kochan NA, et al. The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. *PLoS One*. 2015;10:e0142388.
42. Taylor CA, Bouldin ED, McGuire LC. Subjective Cognitive Decline Among Adults Aged ≥ 45 Years - United States, 2015-2016. *MMWR Morb Mortal Wkly Rep*. 2018;67:753–757.
43. Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, et al. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. *Alzheimers Dement*. 2018. doi: 10.1016/j.jalz.2018.07.219. [Epub ahead of print]
44. Jackson JD, Rentz DM, Aghjayan SL, et al. Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. *Age Ageing*. 2017;46:988–93.
45. Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. *Public Health Rep*. 2014;129Suppl2:19–31.
46. Roehr S, Pabst A, Luck T, Riedel-Heller SG. Is dementia incidence declining in high-income countries? A systematic review and meta-analysis. *Clin Epidemiol*. 2018;10:1233–47.
47. Prince M, Wimo AGM, Ali GC, Wu YT, Prina M. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer's Disease International; 2015.

48. Mendonca MD, Alves L, Bugalho P. From Subjective Cognitive Complaints to Dementia: Who is at Risk?: A Systematic Review. *Am J Alzheimers Dis Other Demen.* 2016;31:105–14.
49. Roehr S, Luck T, Pabst A, et al. Subjective cognitive decline is longitudinally associated with lower health-related quality of life. *Int Psychogeriatr.* 2017;29:1939–50.
50. Waldorff FB, Siersma V, Waldemar G. Association between subjective memory complaints and health care utilisation: a three-year follow up. *BMC Geriatr.* 2009;9:43.
51. Bhome R, Berry AJ, Huntley JD, Howard RJ. Interventions for subjective cognitive decline: systematic review and meta-analysis. *BMJ Open.* 2018;8:e021610.
52. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet.* 2017;390:2673–734.

Table 1. Contributing studies (n = 16).

Study	Abbreviation	Country	Country income group*	Baseline (years)	Sample size
Atma Jaya Cognitive & Aging Research	ActiveAging	Indonesia	LMIC	2009	278
Cognitive Function & Ageing Studies	CFAS	UK	HIC	1989-1991	12,457
Einstein Aging Study USA	EAS	USA	HIC	1993	2,154
Epidemiology of Dementia in Central Africa	EPIDEMCA	Republic of Congo, Central African Republic	LIC/LMIC	2011-2012	1,867
Etude Santé Psychologique et Traitement	ESPRIT	France	HIC	1999-2001	2,190
Invecchiamento Cerebrale in Abbiategrasso	Invece.Ab	Italy	HIC	2010	1,280
Korean Longitudinal Study on Cognitive Aging and Dementia	KLOSCAD	Korea	HIC	2009-2012	6,430
Leipzig Longitudinal Study of the Aged	LEILA75+	Germany	HIC	1997	1,045
Long-term Research Grant Scheme - Towards Useful Aging	LRGS-TUA	Malaysia	UMIC	2012-2013	2,131
Maastricht Aging Study	MAAS	Netherlands	HIC	1993	500
Monongahela Valley Independent Elders Survey	MoVIES	USA	HIC	1987-1989	1,276
Personality and Total Health Through Life Project	PATH	Australia	HIC	2001	1,965
Sasaguri Genkimon Study	SGS	Japan	HIC	2011	2,618
Singapore Longitudinal Ageing Studies II	SLASII	Singapore	HIC	2003	2,585
Sydney Memory and Ageing Study	SydneyMAS	Australia	HIC	2005-2007	1,037
Zaragoza Dementia Depression Project	ZARADEMP	Spain	HIC	1994	4,415

Abbreviations: HIC = high-income country, LIC = low-income country, LMIC = lower-middle income country, UMIC = upper-middle income country; *according to World Bank classification at year/mean year of baseline assessment

Table 2. Baseline characteristics of the analytical sample (n = 39,387).

Study	Country	Sample size	Age <i>M (SD; R)</i>	Females (%)	Education in years <i>M (SD)</i>	Main ethnicity
ActiveAging	Indonesia	260	68.60 (7.66; 60-97)	64.2	6.21 (4.73)	Asian
CFAS	UK	11,363	74.82 (6.64; 64-105)	59.2	10.03 (2.28)	White
EAS	USA	1,950	78.53 (5.34; 64-100)	61.3	13.26 (3.59)	White (66.6%), African American/Black (27.0%)
EPIDEMCA	Republic of Congo, Central African Republic	1,736	72.74 (6.44; 65-99)	60.4	2.06 (3.86)	African/Black
ESPRIT	France	2,022	73.09 (5.50; 65-96)	58.0	12.34 (2.26)	White
Invece.Ab	Italy	1,142	72.15 (1.28; 70-75)	53.9	7.00 (3.27)	White
KLOSCAD	Korea	5,784	69.78 (6.48; 60-96)	55.7	8.37 (5.29)	Asian
LEILA75+	Germany	875	81.51 (4.87; 75-99)	73.6	11.95 (1.81)	White
LRGS-TUA	Malaysia	1,964	68.60 (5.94; 60-92)	50.2	5.47 (3.97)	Asian
MAAS	Netherlands	457	68.94 (6.02; 60-83)	49.5	9.47 (2.82)	White
MoVIES	USA	1,188	74.06 (5.35; 66-97)	60.4	11.30 (2.48)	White
PATH	Australia	1,469	70.60 (1.49; 68-74)	49.7	14.08 (2.67)	White
SGS	Japan	1,948	73.44 (6.05; 65-93)	58.0	11.10 (2.50)	Asian
SLAS II	Singapore	2,364	69.02 (6.71; 60-94)	60.7	5.41 (4.17)	Asian
SydneyMAS	Australia	966	78.85 (4.82; 70-91)	55.2	11.63 (3.49)	White
ZARADEMP	Spain	3,899	73.15 (9.20; 60-102)	56.5	7.18 (3.83)	White
Total	N/A	39,387	73.07 (7.08; 60-105)	57.7	9.13 (4.43)	N/A

Abbreviations: M = mean; N/A = not applicable; R = range; SD = Standard deviation

Table 3. Study-based age- and gender-standardized prevalence estimates for subjective cognitive decline (SCD; last column) and cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to qualitative harmonization.

Study	SCD operationalization criteria			
	Criterion 1 Endorsement of a self-experienced decline in cognitive capacity without objective cognitive impairment	+ Criterion 2 Intact functional ability	+ Criterion 3 No major depression	+ Criterion 4 No anxiety disorder
	% (95%CI)			
ActiveAgeing	27.98 (21.44-34.52)	25.81 (19.41-32.20)	25.73 (19.36-32.10)	N/A
CFAS	17.04 (15.45-18.64)	15.59 (14.00-17.18)	12.73 (11.41-14.05)	6.34 (5.57-7.20)
EAS	15.84 (12.57-19.10)	13.82 (10.90-16.73)	15.23 (10.95-19.51)	12.05 (5.80-18.30)
EPIDEMCA	50.52 (48.36-52.69)	47.74 (45.51-49.98)	25.83 (23.80-27.86)	23.86 (21.93-25.79)
ESPRIT	18.17 (16.52-19.82)	16.60 (15.02-18.18)	13.36 (11.92-14.80)	10.35 (9.11-11.60)
Invece.Ab	14.60 (11.63-17.56)	14.02 (10.89-17.16)	12.31 (9.43-15.18)	10.76 (8.28-13.23)
KLOSCAD	63.65 (62.28-65.02)	58.02 (57.88-59.46)	42.25 (40.82-43.68)	42.27 (40.90-43.66)
LEILA75+	12.88 (11.65-14.12)	11.70 (10.48-12.92)	9.80 (8.64-10.96)	N/A
LRGS-TUA	51.23 (48.15-54.31)	47.39 (44.32-50.47)	46.84 (43.80-49.87)	N/A
MAAS	65.26 (60.33-70.20)	60.52 (55.35-65.69)	54.97 (49.43-60.50)	52.70 (47.43-57.96)
MoVIES	32.82 (30.35-35.32)	30.45 (28.01-32.90)	27.27 (24.89-29.65)	N/A
PATH	8.95 (7.89-10.01)	8.23 (7.21-9.26)	7.34 (6.36-8.33)	6.06 (5.13-6.99)
SGS	18.47 (16.82-20.13)	16.52 (14.93-18.10)	10.24 (8.94-11.55)	9.91 (8.64 (11.18)
SLAS II	12.16 (10.53-13.79)	10.82 (9.27-12.36)	10.28 (8.78-11.78)	9.89 (8.50-11.28)
SydneyMAS	42.77 (40.49-45.04)	39.10 (36.70-41.51)	32.58 (30.14-35.01)	26.98 (24.55-29.40)
ZARADEMP	44.68 (42.98-46.38)	42.04 (40.31-43.77)	29.42 (27.77-31.06)	28.12 (26.50-29.74)
Total*	33.03 (32.56-33.49)	30.46 (30.01-30.92)	24.08 (23.65-24.51)	23.83 (23.29-24.36)

Abbreviations: 95% CI = 95% confidence interval; N/A = not available; *unstandardized

Table 4. Study-based age- and gender-standardized prevalence estimates for subjective cognitive decline (SCD; last column) and cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to quantitative harmonization/Item response Theory (IRT) modelling.

Study	SCD operationalization criteria			
	Criterion 1 Endorsement of a self-experienced decline in cognitive capacity without objective cognitive impairment	+ Criterion 2 Intact functional ability	+ Criterion 3 No major depression	+ Criterion 4 No anxiety disorder
	Prevalence estimates in % (95%CI)			
ActiveAgeing	27.97 (21.43-34.51)	25.80 (19.40-32.20)	25.73 (19.36-32.10)	N/A
CFAS	23.44 (21.77-25.12)	21.59 (19.91-23.26)	17.78 (16.36-19.20)	9.60 (8.63-10.58)
EAS	50.41 (45.20-55.62)	46.06 (41.06-51.06)	38.71 (34.07-43.34)	25.91 (19.33-32.48)
EPIDEMCA	56.28 (54.18-58.38)	53.02 (50.83-55.21)	30.64 (28.51-32.77)	28.41 (26.38-30.44)
ESPRIT	31.26 (29.34-33.18)	28.76 (26.89-30.63)	23.97 (22.20-25.74)	18.94 (17.36-20.51)
Invece.Ab	14.61 (11.64-17.58)	14.03 (10.90-17.17)	12.32 (9.44-15.20)	10.77 (8.28-13.26)
KLOSCAD	55.51 (54.09-56.92)	50.55 (49.10-52.00)	36.01 (34.62-37.40)	35.97 (34.62-37.31)
LEILA75+	12.89 (11.66-14.13)	11.71 (10.49-12.94)	9.81 (8.65-10.97)	N/A
LRGS-TUA	51.23 (48.15-54.31)	47.40 (44.32-50.47)	46.84 (43.80-49.87)	N/A
MAAS	65.26 (60.32-70.20)	60.52 (55.34-65.69)	54.97 (49.43-60.51)	52.70 (47.43-57.98)
MoVIES	29.39 (26.97-31.81)	27.20 (24.83-29.57)	23.87 (21.59-26.15)	N/A
PATH	11.68 (10.50-12.86)	10.76 (9.62-11.90)	9.63 (8.54-10.73)	7.83 (6.80-8.87)
SGS	18.47 (16.81-20.12)	16.51 (14.93-18.09)	10.24 (8.93-11.54)	9.91 (8.64-11.18)
SLAS II	25.48 (23.37-27.59)	22.87 (20.83-24.91)	22.17 (20.16-24.18)	21.18 (19.31-23.05)
SydneyMAS	45.81 (43.41-46.39)	42.72 (40.48-44.95)	35.87 (33.55-38.19)	29.88 (27.54-32.22)
ZARADEMP	44.69 (42.99-46.39)	42.04 (40.32-43.77)	30.64 (28.51-32.77)	28.12 (26.50-29.74)
Total*	37.32 (36.85-37.79)	34.49 (34.02-34.97)	27.75 (27.31-28.20)	25.60 (25.06-26.14)

Abbreviations: 95% CI = 95% confidence interval; N/A = not available; *unstandardized




Figure 1. SCD prevalence according to age groups and gender in older individuals (≥ 60 years) without cognitive impairment across international cohort studies (percentages). Estimates are based on Item response Theory (IRT) analysis.